A detailed history of Federated Hermes, Inc. transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 3,117 shares of ITOS stock, worth $25,652. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,117
Previous 1,805 72.69%
Holding current value
$25,652
Previous $26,000 19.23%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.09 - $17.97 $13,238 - $23,576
1,312 Added 72.69%
3,117 $31,000
Q2 2024

Aug 08, 2024

SELL
$10.33 - $18.09 $9,142 - $16,009
-885 Reduced 32.9%
1,805 $26,000
Q1 2024

May 14, 2024

SELL
$9.89 - $13.64 $2,512 - $3,464
-254 Reduced 8.63%
2,690 $36,000
Q4 2023

Jan 31, 2024

BUY
$8.57 - $11.06 $24,698 - $31,874
2,882 Added 4648.39%
2,944 $32,000
Q3 2023

Nov 13, 2023

SELL
$10.95 - $14.6 $25,338 - $33,784
-2,314 Reduced 97.39%
62 $0
Q2 2023

Aug 14, 2023

SELL
$12.93 - $18.05 $131,278 - $183,261
-10,153 Reduced 81.04%
2,376 $31,000
Q1 2023

May 08, 2023

SELL
$13.02 - $22.62 $625,272 - $1.09 Million
-48,024 Reduced 79.31%
12,529 $170,000
Q4 2022

Feb 13, 2023

SELL
$17.77 - $21.6 $1.82 Million - $2.21 Million
-102,198 Reduced 62.79%
60,553 $1.18 Million
Q3 2022

Nov 14, 2022

SELL
$18.6 - $27.25 $450,919 - $660,621
-24,243 Reduced 12.96%
162,751 $3.1 Million
Q2 2022

Aug 15, 2022

SELL
$16.57 - $35.1 $534,846 - $1.13 Million
-32,278 Reduced 14.72%
186,994 $3.85 Million
Q1 2022

May 13, 2022

BUY
$31.92 - $47.45 $3.94 Million - $5.86 Million
123,474 Added 128.89%
219,272 $7.06 Million
Q4 2021

Feb 14, 2022

BUY
$26.23 - $47.86 $2.51 Million - $4.58 Million
95,798 New
95,798 $4.46 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $293M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.